Latest News of BMRN
Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN)
By Yahoo! Finance |
4 days ago
Biomarin Pharmaceutical Inc shows financial growth in its 10-Q report, with a focus on rare-disease therapies. Despite revenue increase, rising operating expenses require careful management. Market le...
Biomarin Pharmaceutical Inc (BMRN) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...
By Yahoo! Finance |
6 days ago
BMN 333 aims to enhance CNP's half-life for improved effects in skeletal disorders. The trial length and expansion into other indications are flexible based on data. Factors impacting financials inclu...
BioMarin Pharmaceutical (BMRN): Hedge Funds Back Biotech Leader Amid Record Revenue Growth
By Yahoo! Finance |
1 week ago
Goldman Sachs predicts a drop in S&P 500 returns due to market concentration in top stocks. They suggest the growth rate will decline as it's hard to sustain high levels for long. Despite this, they f...
-
BioMarin Pharmaceutical Inc. (BMRN): Is This Biotech Stock A Good Buy?
By Yahoo! Finance | 1 month agoThe article discusses the top biotech stocks to invest in, focusing on BioMarin Pharmaceutical Inc. It highlights the growth potential of the biotechnology industry, market trends, stock analysis, and...
-
BioMarin Pharmaceutical Inc (BMRN): Are Hedge Funds Bullish on This Elliott Management-Approved Stock Now?
By Yahoo! Finance | 2 months agoElliott Management's top 10 stock picks include BioMarin Pharmaceutical Inc (BMRN). The hedge fund, led by billionaire Paul Singer, is known for successful investments in underperforming companies and...
-
Here's Why Parnassus Value Equity Fund Sold BioMarin Pharmaceutical (BMRN)
By Yahoo! Finance | 4 months agoParnassus Investments' "Parnassus Value Equity Fund" outperformed the Russell 1000 Value Index in Q1 2024. Key contributors were stock selections in IT and Communication sectors. BioMarin Pharmaceutic...
-
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 41% Below Their Intrinsic Value Estimate
By Yahoo! Finance | 4 months agoThe fair value estimate for BioMarin Pharmaceutical is 32% higher than the analyst price target. Using a 2-stage DCF model, the intrinsic value is estimated at US$27 billion, indicating the stock is u...
-
Should You Hold BioMarin Pharmaceutical (BMRN) Despite Setback?
By Yahoo! Finance | 4 months agoScout Investments, Inc, under Carillon Tower Advisers, released the Q1 2024 investor letter for the "Carillon Scout Mid Cap Fund." The letter discusses market trends, highlights like BioMarin Pharmace...